Literature DB >> 22767102

Interaction of a ruthenium hexacationic prism with amino acids and biological ligands: ESI mass spectrometry and NMR characterisation of the reaction products.

Lydia E H Paul1, Bruno Therrien, Julien Furrer.   

Abstract

Reactions between the cationic triangular metallaprism [(p-cymene)(6)Ru(6)(tpt)(2)(dhnq)(3)](6+) ([1](6+)) [tpt is 2,4,6-tri(pyridine-4-yl)-1,3,5-triazine; dhnq is 5,8-dihydroxy-1,4-naphthoquinonato] and Arg, His, Lys, ascorbic acid, lactic acid and glutathione (GSH) have been studied at 37 °C in aqueous solution at pD 7 using NMR spectroscopy and electrospray ionisation mass spectrometry. Coordination to the imidazole nitrogen atom of His or to the basic NH/NH(2) groups in Arg and Lys slowly displaces the dhnq and tpt ligands from the (p-cymene)Ru units, and subsequently additional coordination to the amino and carboxylato groups forms stable N,N,O metallacycles. Compared with our previously reported study with the analogous metallaprism [(p-cymene)(6)Ru(6)(tpt)(2)(dhbq)(3)](6+) ([2](6+)) (dhbq is 2,5-dihydroxy-1,4-benzoquinonato), the larger metallaprism [1](6+) appears to be significantly more stable, and disassembled in the presence of Arg, His and Lys after only 12 h of incubation. Moreover, the reaction with His is not complete, since only 14 % of His reacted after more than 1 week of incubation. Solutions of [1](6+) are also able to catalyse oxidation of the thiol group of Cys and GSH to give the corresponding disulfides and of ascorbic acid to give the corresponding dehydroascorbic acid. However, the results are markedly different from those obtained with metallaprism [2](6+): the oxidation of Cys and ascorbic acid is not complete, and the formation of intermediate adducts could be evidenced. On the other hand, the oxidation of GSH remains fast and is completed after only 12 h. Oxidation of GSH to give the corresponding disulfide may explain its higher in vitro anticancer activity as compared with [2](6+). Our results suggest that metallaprism [1](6+) is more robust than [2](6+), may remain intact in the bloodstream and, therefore, may enter cancer cells undamaged, thus confirming the drug delivery potential for such water-soluble organometallic cages.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22767102     DOI: 10.1007/s00775-012-0918-8

Source DB:  PubMed          Journal:  J Biol Inorg Chem        ISSN: 0949-8257            Impact factor:   3.358


  31 in total

1.  Double targeting of tumours with pyrenyl-modified dendrimers encapsulated in an arene-ruthenium metallaprism.

Authors:  Anaïs Pitto-Barry; Nicolas P E Barry; Olivier Zava; Robert Deschenaux; Paul J Dyson; Bruno Therrien
Journal:  Chemistry       Date:  2011-01-05       Impact factor: 5.236

Review 2.  Interactions of antitumor metallodrugs with serum proteins: advances in characterization using modern analytical methodology.

Authors:  Andrei R Timerbaev; Christian G Hartinger; Svetlana S Aleksenko; Bernhard K Keppler
Journal:  Chem Rev       Date:  2006-06       Impact factor: 60.622

3.  Evidence for drug release from a metalla-cage delivery vector following cellular internalisation.

Authors:  Olivier Zava; Johan Mattsson; Bruno Therrien; Paul J Dyson
Journal:  Chemistry       Date:  2010-02-01       Impact factor: 5.236

4.  Efficient oxidation of cysteine and glutathione catalyzed by a dinuclear areneruthenium trithiolato anticancer complex.

Authors:  Federico Giannini; Georg Süss-Fink; Julien Furrer
Journal:  Inorg Chem       Date:  2011-10-07       Impact factor: 5.165

5.  The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes.

Authors:  B Rosenberg; L Van Camp; E B Grimley; A J Thomson
Journal:  J Biol Chem       Date:  1967-03-25       Impact factor: 5.157

Review 6.  Metal-based antitumour drugs in the post genomic era.

Authors:  Paul J Dyson; Gianni Sava
Journal:  Dalton Trans       Date:  2006-03-28       Impact factor: 4.390

7.  Investigation of the reactivity between a ruthenium hexacationic prism and biological ligands.

Authors:  Lydia E H Paul; Bruno Therrien; Julien Furrer
Journal:  Inorg Chem       Date:  2011-12-23       Impact factor: 5.165

8.  Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound.

Authors:  Alberta Bergamo; Alessia Masi; Paul J Dyson; Gianni Sava
Journal:  Int J Oncol       Date:  2008-12       Impact factor: 5.650

9.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.

Authors:  Y Matsumura; H Maeda
Journal:  Cancer Res       Date:  1986-12       Impact factor: 12.701

Review 10.  Anticancer activity of metal complexes: involvement of redox processes.

Authors:  Ute Jungwirth; Christian R Kowol; Bernhard K Keppler; Christian G Hartinger; Walter Berger; Petra Heffeter
Journal:  Antioxid Redox Signal       Date:  2011-05-11       Impact factor: 8.401

View more
  3 in total

1.  Reactivity of hexanuclear ruthenium metallaprisms towards nucleotides and a DNA decamer.

Authors:  Lydia E H Paul; Bruno Therrien; Julien Furrer
Journal:  J Biol Inorg Chem       Date:  2014-11-08       Impact factor: 3.358

2.  Mechanistic study on substitution reaction of a citrato(p-cymene)Ru(ii) complex with sulfur-containing amino acids.

Authors:  Sen-Ichi Aizawa; Kohei Takizawa; Momoko Aitani
Journal:  RSC Adv       Date:  2019-08-13       Impact factor: 4.036

3.  1H HR-MAS NMR Based Metabolic Profiling of Cells in Response to Treatment with a Hexacationic Ruthenium Metallaprism as Potential Anticancer Drug.

Authors:  Martina Vermathen; Lydia E H Paul; Gaëlle Diserens; Peter Vermathen; Julien Furrer
Journal:  PLoS One       Date:  2015-05-29       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.